Medicinski Didušikov Oksid Sol (Nitrous Oxide)

Nitrous oxide acts mainly by blocking NMDA receptors and enhancing GABAergic neurotransmission, which reduces neuronal excitability. It also promotes the release of endogenous opioids and modulates sympathetic activity, producing pain relief, sedation, and loss of consciousness when inhaled.

The dose of nitrous oxide is individualized by the prescriber based on the patient’s age, weight, clinical condition, and the required depth of analgesia or anesthesia. Administration is titrated to effect under continuous monitoring.

Safety data are limited. Nitrous oxide should be used in pregnancy only when the potential benefit justifies the potential risk to the fetus, and it is generally avoided in the first trimester. Limited data exist for breastfeeding, so clinicians should weigh risks and benefits before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Nitrous oxide has a rapid onset and recovery profile, lower potency, and minimal metabolism compared with agents like sevoflurane or desflurane. It is often used as an adjunct to reduce the concentration of more potent anesthetics, but it provides less profound analgesia and may require supplemental oxygen to avoid hypoxia.

Medicinski Didušikov Oksid Sol should be stored at ambient temperature, away from direct sunlight and heat sources. Keep the gas cylinders upright, secured, and in their original packaging to protect the valve and prevent damage.

Nitrous oxide is delivered via a calibrated inhalation system, typically mixed with oxygen. The concentration is adjusted by the anesthetist to achieve the desired level of analgesia, sedation, or anesthesia, while continuous monitoring of respiratory and cardiovascular parameters is maintained.

Serious risks include hypoxia, respiratory depression, severe hypotension, loss of consciousness, and, rarely, pulmonary edema. Prompt recognition and immediate provision of supplemental oxygen are essential to mitigate these complications.

Patients with severe chronic obstructive pulmonary disease, untreated pneumothorax, certain middle‑ear surgeries, or those who are unable to protect their airway should not receive nitrous oxide. It is also contraindicated in individuals with known hypersensitivity to the gas.